---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

---

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

---

 

 

Date of report (Date of earliest event reported):

 

 

March 17, 2004

 

 

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

 

Delaware		000-31145		04-3278032
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

 

 

455 South Gulph Road, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

 

 

(610) 205-2300

(Registrant’s telephone number, including area code)

 

 

---

(Former Name or Former Address, if Changed Since Last Report.)

 

---

---

ITEM  5.

OTHER EVENTS.

 

On March 17, 2004, in a letter addressed to Vicuron Pharmaceuticals Inc. (the “Company”), Claudio Quarta, Ph.D. resigned as Chief Operating Officer of the Company as of March 19, 2004. There were no disagreements between Dr. Quarta and the Company on any matter relating to the Company’s operations, policies or practices.

 

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				VICURON PHARMACEUTICALS INC.
				(Registrant)
Date:		March 19, 2004		By:		/S/    GEORGE F. HORNER III
						George F. Horner III
						President and Chief Executive Officer